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Abstract
Background: Cigarette smoking causes significant morbidity and mortality and is a major public health concern worldwide. 
Primary care doctors are in a unique position that enables them to promote smoking cessation, as smokers are more aware 
of their health at the time of their clinic visit. It is thus important to offer effective treatment to help smokers stop smoking.
Methods: A search of PubMed was done up to 16 December 2009, using the keywords “varenicline” alone, “varenicline” 
and “family medicine”, and “varenicline” and “primary care”. The search produced 426 articles on varenicline. The articles 
that were chosen were case reports, meta-analyses, review articles and clinical trials published in English.
Results: A new drug called varenicline has recently been introduced to assist smoking cessation. It is an α4β2 nicotinic 
acetylcholine receptor partial agonist. Varenicline has a unique action that relieves the cravings and withdrawal symptoms 
that occur during smoking abstinence, while blocking the receptor and preventing any reward from additional smoking. 
It has been shown to be efficacious for smoking cessation in normal smokers; however, its safety in smokers with mental 
health problems needs to be elucidated.
Conclusion: The currently available data support the effectiveness of varenicline to treat nicotine dependence, but caution 
is needed in smokers with mental health problems. Thus, primary care doctors have a new pharmacological option to offer 
smokers who wish to stop smoking. 
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Introduction
Cigarette smoking is the single most important modifiable 
risk factor for cardiovascular disease. It also causes 
respiratory diseases, cerebrovascular diseases and cancer. 
Globally there are 1.3 billion smokers, and the majority of 
these are from developing countries.1 The prevalence of 
smoking is 23% in the USA, 67% in China and 75% in 
Yemen. The present trend of smoking seen worldwide is 
also observed in Africa. The Medical Research Council 
(MRC) estimates that 8% of South African deaths are due 
to smoking, and the World Health Organization (WHO) has 
reported that smoking causes five million deaths per year. If 
the present trend continues, it is projected that, by the year 
2025, up to 10 million smokers will die annually.2 There is, 
therefore, an urgent need to identify an effective treatment 
to help smokers stop smoking.
Up to 70% of smokers visit a primary care doctor each 
year.3 Smokers have also been reported to be more aware 
of their health during these clinic visits. A primary care 
doctor thus has an important role, as the clinic visit provides 
an opportunity to offer smoking cessation interventions for 
smokers. Primary care doctors are also in a unique position 
as agents for smoking cessation because of their unique, 
personal doctor-patient relationship and their provision of 
comprehensive care. Primary care clinics are also more 
easily accessible to patients needing close supervision 
and support. It has been shown that brief advice offered 
by primary care doctors increases the rates of smoking 
cessation, but the addition of pharmacotherapy further 
enhances cessation outcomes.3
In recent years, much work has been published regarding 
what is effective in smoking cessation.4 The combined 
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use of pharmacotherapy and behavioural modification 
has consistently produced long-term smoking abstinence. 
A variety of pharmacological options are available to help 
smokers stop smoking. These options include nicotine-
based medications, such as nicotine replacement therapy, 
and non-nicotine-based medications, such as buproprion, 
clonidine and nortriptyline.5 A new pharmacological 
agent called varenicline has recently been approved as a 
pharmacological agent for smoking cessation.5 Varenicline 
has been reported to have unique properties that help 
smokers refrain from smoking again.6
Why do smokers need to stop smoking?
The benefits of stopping smoking are well documented. By 
stopping smoking, a smoker gains short-term and long-
term health benefits, reduces morbidity and mortality, and 
reverses disease progression associated with smoking.7 
The risk of dying from heart disease is 70% greater in people 
who smoked compared to people who did not. Compared 
to a non-smoker, a cigarette smoker has an increased risk 
of hospitalisation due to heart failure and heart attack. 
However, people who quit smoking have been shown to 
have less risk of death due to heart disease. For instance, 
quitting smoking at the age of 35 increases life expectancy 
by 6.9 to 8.5 years for men and 6.1 to 7.7 years for women.8 
Quitting smoking also reduces the risk of death for patients 
with left-heart failure and those who have undergone heart 
bypass surgery. 
Lung function starts to improve within three months of 
quitting and ex-smokers experience decreased coughing, 
sinus congestion, fatigue and shortness of breath.9 The 
risk of coronary heart disease is reduced by 50% among 
ex-smokers one year after quitting and, by five years, the 
risk of stroke returns to the level of people who have never 
smoked. By 10 years after quitting, the risk of lung cancer 
reduces to 30 to 50% of those who continue to smoke 
and, by 15 years, the risk of cardiovascular heart disease 
becomes similar to those who have never smoked.7,9,10 Thus, 
smoking cessation increases life expectancy regardless of 
age at quitting, although the effect is better when quitting at 
an earlier age, in those who smoked fewer cigarettes and in 
those who smoked for fewer years.9 For example, stopping 
smoking at the age of 30 was shown to avoid smoking-
related mortality, whereas stopping smoking at the age of 
50 reduces the risk of death from smoking by half.11 
Source of data
A search of the literature up to 16 December 2009 was 
conducted using PubMed, with keywords “varenicline” 
alone, “varenicline” and “family medicine”, and “varenicline” 
and “primary care”. The search produced a total of 426 
articles on varenicline. The articles chosen were narrowed 
to those published in English and limited to studies done 
on human subjects. Case reports, meta-analyses, review 
articles and clinical trials evaluating the safety, efficacy and 
adverse effects of varenicline were included.6,12-21 
Nicotine dependence 
Nicotine is responsible for the highly addictive nature of 
cigarette smoking. Stopping smoking is difficult because of 
nicotine dependence. Nicotine dependence is characterised 
by loss of control and compulsive drug-seeking behaviour. 
When inhaled, the nicotine in cigarette smoke is absorbed by 
the pulmonary alveoli, passes into the blood and enters the 
brain in less than 10 seconds.22 The nicotine concentration 
in the blood rises rapidly and this phenomenon is known as 
nicotine boost. The extent of nicotine boost varies between 
individuals, but the nicotine concentration in the arteries is 
about twice the concentration in the veins.23 In the brain, 
nicotine binds to the nicotinic acetylcholine receptors at the 
α4β2 subunit.22
Varenicline
Varenicline is a partial agonist at the α4β2 nicotinic 
acetylcholine receptor developed specifically for smoking 
cessation. Varenicline as the tartrate salt has a molecular 
weight of 361.35 daltons and a molecular formula of C13H13N3 
• C4H6O6.
5 It stimulates dopamine release upon binding to 
the α4β2 receptor. However, the dopamine release from the 
ventral tegmental area due to varenicline is less (32 to 45%) 
when compared to the effect of nicotine.5 Thus, cravings 
and withdrawal symptoms are partially reduced. Another 
feature of varenicline is the high affinity for the receptor, 
causing it to remain bound to the receptor for a time. This 
impedes the ability of nicotine to activate the receptor and 
thus reduces the satisfaction of smoking a cigarette.4
A smoker who is motivated to stop smoking is encouraged 
to set a date to stop smoking, and varenicline is prescribed 
one week before the quit date. The initial dose is 0.5 mg 
daily for the first three days. This is gradually increased to 
0.5 mg twice daily for another four days, and then further 
increased on day 8 to 1 mg twice daily.4,6 The recommended 
treatment is for 12 weeks, although an additional 12 weeks 
of treatment may be offered to successful patients at the 
end of the 12 weeks to ensure abstinence.24 
Each varenicline tablet is recommended to be taken with 
food or drink (a glass of water) to reduce nausea. The 
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gradual titration is also done to reduce the incidence of 
nausea, which is the commonest side effect. The dose may 
be lowered temporarily or permanently to 0.5 mg twice 
daily in patients who cannot tolerate the adverse effects of 
varenicline. Other reported adverse events are abnormal 
dreams, insomnia and headache.24 The rare side effects 
reported were changes in taste, vomiting, abdominal pain, 
flatulence and constipation. Drowsiness is a listed adverse 
reaction, thus primary care professionals who prescribe 
varenicline should warn patients who drive or operate 
machinery. Most of the side effects of varenicline are mild 
and can be treated with symptomatic medication.24,25 
Use in special populations
Although varenicline is reported to be generally safe, 
some precaution is required in certain special populations. 
Varenicline undergoes minimal metabolism and 92% is 
excreted unchanged in the urine. In the elderly (geriatric) 
population, a pharmacokinetic study of varenicline 
demonstrated that it is well tolerated by smokers aged 65 
to 75 years. Nevertheless, as elderly patients are more likely 
to have decreased renal function, renal function should be 
monitored when prescribing varenicline. 
Varenicline may be considered for patients with mild renal 
impairment.6,24 Dosage adjustment is not necessary for 
patients with mild (estimated creatinine clearance >  50 
ml/min and ≤  80 ml/min) to moderate renal impairment 
(estimated creatinine clearance 30 ml/min). Patients with 
severe renal impairment (estimated creatinine clearance 
> 50 ml/min and ≤ 80 ml/min) are recommended to start with 
0.5 mg daily and titrated as needed to a maximum dose of 
0.5 mg twice daily. Patients with end-stage renal disease 
who are undergoing haemodialysis should be prescribed a 
maximum of 0.5 mg once daily.25 
Thus far, no inhibition of cytochrome P450 enzymes has been 
reported, and no clinically meaningful drug interactions have 
been identified. Due to the absence of significant hepatic 
involvement, varenicline is thus unaffected in those with 
liver insufficiency. Based on current data, it is recommended 
that varenicline not be prescribed for smokers younger than 
18 years, as the safety and effectiveness of varenicline has 
not been established in this age group. Similarly, varenicline 
is not recommended for smokers who are pregnant or 
breastfeeding, as there are no adequate and well-controlled 
studies of this group. 
Special precaution in patients with mental 
health problems
The efficacy and safety of varenicline in smokers have been 
established in randomised, double-blind, placebo-controlled 
trials.18-20 However, the safety of varenicline in patients with 
mental health problems is questionable.6,26-30 One report 
found varenicline to be safe for patients with mental health 
problems and that it was superior in maintaining smoking 
abstinence. That study was a non-randomised study of 412 
smokers in a community clinic that included 111 patients 
with mental health problems (the primary diagnoses 
were depression (64), bipolar disorder (14), psychosis (7), 
psychosis and depression (24) and eating disorder (2)). 
However, no firm conclusion can be drawn, as the sample 
size of the study was small and the study included varying 
psychiatric diagnoses.6 On the other hand, the literature 
has also reported several cases of neuropsychiatric 
symptoms such as suicidal ideation, suicidal behaviour, 
erratic behaviour and drowsiness as a result of varenicline 
use.31 There have also been reports of activated psychotic 
relapse in schizophrenia, hypomania with agitation in a 
bipolar II disorder, and induction of a manic episode in a 
bipolar patient.26,32 Also published was a case of a person 
who shot his neighbour while in a state of delirium caused 
by taking varenicline with a high dose of alcohol, though it 
was unclear whether the episode was related to the drug 
or to a state of alcoholic intoxication. Other post-marketing 
reports included agitation and depression.33 Most recently, 
acute hepatic injury with raised liver enzymes was reported 
in an alcoholic patient. The level of the alkaline phosphatase 
enzyme was reported to reduce to normal within one month 
of discontinuation of varenicline, and the level of the enzyme 
aminotransferase was shown to reduce to normal after four 
months of discontinuation of the drug. 
In all the examples stated above, it was not clear whether the 
psychiatric symptoms were related to the drug or to nicotine 
withdrawal symptoms, and a causal connection or lack of 
connection between varenicline and these symptoms was 
not established.24 However, the Diagnostic and Statistical 
Manual of Mental Disorders (4th edition) has acknowledged 
that the psychological symptoms of nicotine withdrawal 
include insomnia, irritability, frustration or anger, anxiety, 
difficulty concentrating, restlessness, and a dysphoric and 
depressed mood.34 Varenicline is also reported to cause 
dysregulation of the dopaminergic system, and this 
may lead to the exacerbation of psychotic symptoms 
in patients with psychotic disease. Varenicline has 
also been linked to neuronal α7 nAChR1, which is 
linked to major psychiatric disorders.26,32 
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Thus, when prescribing varenicline to mental health patients, 
primary care doctors need to consider the beneficial 
and adverse effects of varenicline. Prior to prescribing 
varenicline, it is thus important to establish the presence of 
mental health problems. Based on current information and 
on the knowledge from the literature, it is recommended 
that: (1) Patients with mental health problems, their families 
and carers should be given advice and alerted to the risk 
of varenicline in relation to their existing mental illness. 
(2) Alternative pharmacotherapy should be considered for 
smokers with mental health problems who wish to stop 
smoking, as thus far there is insufficient data to certify the 
safety of varenicline for this population. (3) For smokers with 
mental health problems who choose to take varenicline, 
advice should be given to their families and carers to be 
alert to changes in mood and behaviour. Patients who 
develop agitation, hostility, depressed mood or suicidal 
thoughts should be advised to stop taking varenicline and 
contact their doctor immediately. 
Comparing the effectiveness and safety of 
varenicline with other available treatments 
for smoking cessation 
A study of smokers in a primary care setting reported that 
54.6% of smokers treated with varenicline were abstinent 
at 12 weeks compared to those on placebo (11.6%). At 52 
weeks, smokers on varenicline (22.4%) were still superior 
in their abstinence to the placebo group (3.9%).24 A meta-
analysis report also showed that varenicline tripled the 
success rate compared to a placebo, and that it was more 
effective than other medications used singly.5 Varenicline 
was also reported to be superior to nicotine patches in 
producing continuous abstinence rates by week 4 and 
at one year after stopping smoking.35 A recent report 
that evaluated the cost-effectiveness of varenicline and 
nicotine replacement therapy (NRT) for smoking cessation 
in four European countries (Belgium, France, Sweden and 
the UK) also found varenicline to be superior to NRT. This 
study compared smoking-related morbidity and mortality 
and the quality of the adjusted life-years gained and found 
varenicline to be more cost-effective than NRT.36 Varenicline 
was also found to be more cost-effective and cost-saving 
compared to other smoking cessation treatments such as 
bupropion and nortriptyline.4
Varenicline in the family practice setting
Varenicline has been used widely in primary care settings 
in developed countries.4,6,24,25,37 It was licensed for use in 
the USA in May 2006 and in Europe in September 2006. 
Varenicline is also now prescribed in primary care settings 
in the UK under the National Health Service.6,37 However, 
despite offering a new option for smoking cessation, the 
latest literature reports have raised numerous issues 
pertaining to varenicline.24,25 Besides medication, primary 
care doctors should also take account of the importance of 
motivating the patient to stop smoking and that the success 
of drug treatment is dependent on its combination with 
behavioural intervention. 
Promoting smoking cessation is an achievable task and 
is not time consuming. Brief interventions, which include 
simple inquiry (ask, advise, assess, assist and arrange to 
stop smoking), take less than three minutes to perform 
and should be offered to all smokers.4 Unfortunately most 
doctors and health professionals in the primary care settings 
are not trained formally in smoking cessation and some 
have misconceptions about how best to help a smoker stop 
smoking and what should constitute a smoking cessation 
programme. There is, thus, a need for formal training for 
health professionals interested in offering smoking cessation 
services to primary care patients.
Conclusion
Cigarette smoking continues to be an important cause 
of morbidity and mortality worldwide. Effective smoking 
cessation treatment is thus needed to curb this public 
health problem. Due to its unique partial agonist property, 
varenicline – a new class of drug for smoking cessation – is 
a valuable addition to the existing pharmacological agents 
for smoking cessation. In general, varenicline has the 
potential to be highly effective in promoting and maintaining 
smoking abstinence, although its safety in smokers with 
mental health problems needs to be established further. 
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